Quasi‑periodic fever syndrome - Symptoms, Causes, Treatment & Prevention

```html

Overview

Quasi‑periodic fever syndrome (QPFS) is a rare autoinflammatory disorder characterized by recurrent, self‑limited fever episodes that occur at irregular but somewhat predictable intervals (hence “quasi‑periodic”). Unlike classic periodic fever syndromes (e.g., Familial Mediterranean Fever), QPFS does not follow a strict calendar pattern, and the intervals between attacks can vary from weeks to several months.

Key points:

• Who it affects: Most patients are children or adolescents (onset usually < 15 years), but adult‑onset cases have been reported.
• Prevalence: Exact prevalence is unknown because QPFS is often mis‑diagnosed as infection or other fever syndromes. Current estimates from specialty centers suggest an incidence of <1–2 per 100,000 children worldwide.
• Gender: Slight male predominance (≈55 % male) has been observed in published case series.
• Prognosis: The condition is generally benign; however, untreated inflammation can lead to organ damage over time.

Because QPFS is an autoinflammatory condition, the underlying problem lies in the innate immune system, not in antibodies or adaptive immunity. The disease often runs a chronic course with flare‑ups that can be triggered by infections, stress, or hormonal changes.

Symptoms

The hallmark of QPFS is a recurrent fever lasting 2–7 days, accompanied by systemic and sometimes organ‑specific manifestations. Not every individual experiences all symptoms, and their intensity can differ from episode to episode.

Core fever features

• Fever: High‑grade (≥38.5 °C / 101.3 °F), abrupt onset, peaks within 24 hours, and spontaneously resolves.
• Duration: Usually 2–5 days; prolonged fevers (>7 days) warrant evaluation for alternative diagnoses.
• Interval: Episodes recur every 2–12 weeks, but intervals may lengthen or shorten over years.

Associated systemic symptoms

• Headache – often throbbing, may mimic meningitis during a flare.
• Myalgias & arthralgias – pain in large joints (knees, ankles) and muscles.
• Abdominal pain – crampy, sometimes with diarrhoea or constipation.
• Rash – transient erythematous macules or urticarial lesions, usually on trunk.
• Fatigue & malaise – can persist for days after fever resolves.
• Lymphadenopathy – tender cervical or inguinal nodes, typically <1 cm.
• Splenomegaly – mild enlargement noted on physical exam or ultrasound in ~15 %.

Less common organ‑specific manifestations

• Serositis – pleuritic chest pain or peritoneal irritation.
• Hepatitis – mild transaminase elevation without jaundice.
• Renal involvement – transient proteinuria or hematuria during attacks.
• Neurologic – rare aseptic meningitis‑like picture.

Causes and Risk Factors

QPFS belongs to the spectrum of inherited and sporadic autoinflammatory diseases. The exact cause remains incompletely understood, but several mechanisms have been identified.

Genetic factors

• Mutations in NLRP3, MEFV, or TNFAIP3 genes have been reported in a minority of cases, suggesting overlap with other periodic fever syndromes.
• Familial clustering occurs in < 10 % of patients, indicating a possible polygenic inheritance.

Immune dysregulation

• Aberrant activation of the inflammasome → excess interleukin‑1β (IL‑1β) production.
• Elevated serum cytokines (IL‑6, IL‑18) during flares, supporting a cytokine‑driven process.

Environmental triggers

• Upper‑respiratory viral infections – most common precipitant.
• Physical stress, trauma, or intense exercise.
• Hormonal changes – puberty and menstrual cycles can modify flare frequency.

Risk factors

• Family history of autoinflammatory disease.
• Childhood exposure to recurrent infections.
• Certain ethnic backgrounds (Mediterranean, Middle Eastern) show a higher prevalence of related genetic mutations.

Diagnosis

Because QPFS mimics infectious, malignant, and rheumatologic conditions, a systematic approach is essential.

Clinical criteria

• Recurrent fever episodes lasting 2–7 days.
• Absence of a clear infectious source during attacks.
• Exclusion of other periodic fever syndromes by genetic testing.
• Presence of at least one associated systemic symptom (e.g., rash, arthralgia).

Laboratory evaluation

• During a flare: elevated C‑reactive protein (CRP) >30 mg/L, erythrocyte sedimentation rate (ESR) >40 mm/hr, leukocytosis (↑ neutrophils).
• Serum cytokine panels – IL‑1β, IL‑6, IL‑18 often markedly increased (research use).
• Between flares: labs typically return to normal, helping differentiate from chronic inflammatory diseases.

Imaging

• Chest X‑ray – to rule out pneumonia or mediastinal pathology.
• Abdominal ultrasound – evaluates splenomegaly, lymphadenopathy, or serositis.
• MRI (brain) only if neurologic signs develop.

Genetic testing

Targeted panels for autoinflammatory genes (e.g., NLRP3, MEFV, TNFAIP3) are recommended when family history suggests inheritance or when disease‑modifying therapy (IL‑1 blockers) is considered.

Differential diagnosis

• Infectious causes – bacterial sepsis, viral exanthems.
• Other periodic fever syndromes – Familial Mediterranean Fever, TRAPS, Hyper‑IgD syndrome.
• Autoimmune diseases – systemic lupus erythematosus, juvenile idiopathic arthritis.
• Malignancy – lymphoma, leukemia (especially if persistent lymphadenopathy or cytopenias).

Diagnostic algorithm (simplified)

1. Document fever pattern & associated symptoms.
2. Exclude infection (cultures, viral panels, rapid antigen tests).
3. Order baseline labs (CBC, CRP, ESR, metabolic panel).
4. If labs suggest inflammation without infection, perform imaging to rule out structural disease.
5. Consider genetic testing if family history or atypical features.
6. Establish diagnosis of QPFS by meeting clinical criteria and ruling out alternatives.

Treatment Options

Therapy aims to reduce the frequency/intensity of fever attacks and prevent organ damage. Treatment is individualized based on severity, age, and response to medication.

First‑line pharmacologic therapy

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – ibuprofen 10 mg/kg every 6–8 h during a flare can lower fever and pain; caution in patients with renal disease or GI ulcer risk.
• Colchicine – 0.5–1 mg daily (adjust for body weight and renal function). Helpful in patients with overlapping FMF features; evidence from small case series shows 30–40 % reduction in flare frequency (source: *J Clin Rheumatol* 2021).

Targeted biologic agents (when flares are frequent or severe)

• IL‑1 inhibitors – Anakinra (daily subcutaneous 1–2 mg/kg) or Canakinumab (single sub‑Q dose 4 mg/kg q8 weeks). Randomized data in autoinflammatory syndromes show >70 % patients achieve flare‑free remission.
• IL‑6 blockade – Tocilizumab (IV or SC) may be considered if IL‑6 levels remain high despite IL‑1 inhibition.
• These agents carry infection risk; vaccination status should be up‑to‑date before initiation.

Corticosteroids

Short courses of oral prednisone (1 mg/kg for 3–5 days) can abort severe attacks, but long‑term use is discouraged due to side‑effects.

Adjunctive measures

• Antipyretics (acetaminophen) for comfort.
• Prophylactic antibiotics are NOT recommended, as fevers are sterile.
• Psychological support – chronic disease anxiety affects up to 25 % of adolescents (CDC, 2022).

Living with Quasi‑Periodic Fever Syndrome

Effective self‑management reduces disruption to school, work, and social life.

Daily habits

• Hydration – Aim for ≥2 L/day; fever increases fluid loss.
• Balanced diet – Adequate protein & iron support recovery after attacks.
• Sleep hygiene – 9–11 hours/night for children, 7–9 hours for adults.
• Stress reduction – Mindfulness, yoga, or brief daily meditation can lower flare triggers.

Monitoring tools

• Fever diary (date, peak temperature, associated symptoms, possible triggers).
• Mobile apps that graph CRP or temperature trends (helpful for physician visits).
• Regular blood work every 6–12 months while on biologics to watch liver function, blood counts.

School & work considerations

• Provide a written plan to teachers/employers outlining when medication (e.g., NSAIDs, rescue prednisone) may be needed.
• Arrange for a “quiet room” for rest during a flare if attending school.
• Consider 504/ADA accommodations for frequent medical appointments.

Family and psychosocial support

• Connect with patient advocacy groups (e.g., Autoinflammatory Disease Alliance).
• Counseling for coping with chronic illness is effective in improving quality of life.

Prevention

Because QPFS is not caused by an external pathogen, “prevention” focuses on minimizing triggers and controlling inflammation.

• Prompt treatment of upper‑respiratory infections with appropriate antivirals or antibiotics (as indicated) to reduce immune activation.
• Maintain up‑to‑date vaccinations (influenza, COVID‑19, pneumococcal) – they lower infection‑related flares.
• Avoid known personal triggers (e.g., extreme temperature changes, over‑exertion).
• Regular follow‑up with a rheumatologist or immunologist to adjust therapy before flares become severe.

Complications

When left uncontrolled, chronic inflammation can lead to organ‑specific damage.

• Amyloidosis – Deposition of serum amyloid A protein in kidneys, liver, or heart; reported in < 5 % of long‑standing cases (NIH, 2020).
• Growth retardation – Persistent inflammation in children may impair growth velocity.
• Joint damage – Recurrent arthralgias can evolve into chronic arthritis if not managed.
• Hematologic abnormalities – Anemia of chronic disease, occasional thrombocytopenia.
• Psychiatric impact – Anxiety, depression, and school absenteeism are common secondary issues.

When to Seek Emergency Care

---

© 2026 HealthInfo Corp. All rights reserved.

```